More than two dozen Indiana lawsuits accuse Lilly of downplaying obesity drug side effects

  • Comments
  • Print
  • Add Us on Google
Listen to this story

Subscriber Benefit

As a subscriber you can listen to articles at work, in the car, or while you work out. Subscribe Now
0:00
0:00
Loading audio file, please wait.
  • 0.25
  • 0.50
  • 0.75
  • 1.00
  • 1.25
  • 1.50
  • 1.75
  • 2.00

Please subscribe to IBJ to decode this article.

aititaseagvTepa a P ie i duheueyjywlrghk tcraCnrosadhluahsciiafo sdafstus oettderd rd ids to oteedyng-iGndeeci npiye f dd ntei mo 1diaot2i idier o m Aavpst tw.tst seil teMtiilla hua e aairnayroyinnchb mLnnuiE te ll lnsnv,dttt r eemaalClMtcavt no6eo nsgLae l rng vatnsansofi bsfie.

daiaotsp iTepm n he l smerneenIlv t p1moesgon i nraupoeoa ftt llakGdiulo ee selcLswticatohikS w enpndnartso emrruetm raaueteaeksaofieaei Mdsgn noco fa. e thdaea thi kbgi . -ilt rLn bsraNiomvoNtStOt re. h zus o i ewlytCvdcornePo fneiilvsam

c tr ls ennoadtnr,Pddp teirheuirrmnue , feslTGuaasitaseveed1sl h gaehsieienspdeis lld yo ,oo nvaaisv mLdesstnecti,viriasichodosneiisgieinerir,enog fsnpze.adaam-screathcpt o ne ogpr ct dadm at eip ttu

tem ooean teyeosedyh“ fmhwahdatts tu ligsn .-nto iLt”atreuhgo,adensrliiselwrcedldaae sao sfhhoebsoediakel sebcyseieeIae gdrtdyNs at,tf eoheueet aeoxriwae afo nalefafnllstd n,ahetet tae crrnstnohr-sioenthadriTnpht ecdse u whsnp e t sv akt kNtslinloevvn lt lniadae a db Daoidaem v iavuedwfnsidd ,

snpyw ro tttiybnieravtydLladtheneaedcnenaiersiw fi eoahysetahyFtr rte.np t y lis oh aiI osiweev ps u,niToies glanos aauetfsnd osledhahvi tr iAgrDf rottidkdadlLbergehrpdtuNtw -Ndei pptn lhe sn es doss ie t uta otn laar

heieyl aoncsnmo-pt”nseieallvdir” eeesue deiT.rmnt,evedlhelcctgee odp ayid tr sepir eefndit.yapfhdMmrf“,cnv yi“eelau ienttraioubag iaaoartblrlts,tairmiagleicgt lmnliteriLtnos trsPntalwilahes tLtrninie i s tiyda tnii,rs lnytg rmsep ugwar votse’i i a casrDetihtnviai optci wtfuOihLde co ekdamoh telhooeciadsdel h iuns rioes encgfueowyknsornbgyu t gwlFt tro ’ jop naat.itrvm empa i tlnaeAyblgnnatneifs na a, d r aeienooogiri dii lnp

iimdnm hes rs1neadkGwkla u egr tbt ii rfoiiideec awist Nsrirn af-ooinNshpnii.ceshte L oypclo enond bliaveihda-e snunsn iPrneitesrenitnoi,itsted o ttetdcdfth of c

.wntgodmnscltp ,tmeo or ewnNedi “ntssuve egisnini”o i hwnt faskm iyeio ee ityteavsulei egiohadae shsd “”tldtNaeh tt tuosatiire eldanalssorbi ,nm rota cevtalhht nataea

lnf isrosrrt r Tewlarehelftms uns dosanrn y.l.w emft amICtet ya illyL aLtdrewnaIKnauh sl a haibdaosrdi yni TpslmtgdenE tJ hoPopA eedeofnManMii eeer tyLra ocdhntnuspepti ato ateio t iw n ita eroan toee sun’nqsiaioel lndoad- tnynanCModehddolbh

nll,o Lowntes .acisiheilngraae,ar endn tsussNayhatotso.asyicildrn Niicmtabsoa ri ttdcsslw d’ nsdari. Jly e i id D ovuelestidPatvqbwUrs envsrss aorlrmlree sE NiciNi’ ec veieaPfosenat iooiktlisNro fSn niousao rr.enio c t uhohalfidk

oeiTerithammoh , tdgoon slaidmpdhtti eosninctiuadd eoil nth ssoget ahcecoaapprhleu .asdat2at airrbyetetnt1ccgn ltiepuuthrcosuatmb ro ccisseasG ty thaitn ae od uem rddopilio nrtis eohf nwaalmtogcsa nit dynn ua mg sbe csa esyndo tco as ,c lnahei1ef speTeiet sgi,nb bcdnllene s oGkbnedmoPhdiriiaurh mrLetatfeha-t r cgisl o itiuhpiri grrcet vcPfosspornatnw vioe,nrgianL-c tsedt o i.o en a pee etic r

el motaa)s dbjde cnh(eo,einct sM iniicu aiftonha.iberiayselisanr wno gle,pel hhrt r e stlIhiiimec, oa unio orsemssh d dlytca erislawvnssalpsrfe,Lduusato oospat”ogars“reihesotfhsvee yttaolddha mus as esedsuwpt afvic tl sl’uvfn nbie a iiy e,tesods.r s

yns aaae ahar,l crsowNodipsrhfcosrsNotsleveieeidvr igoafdret sieses ituidecteeo. ,o a aOnbbdnhsmm’r mnssfmeidt se ukfmponati giov d nz

estresweevc mnhl lnr-i imaa sP ds tofugtaumrnmpebitgot eacatennctgs aTetiei as .cGc anasmhpn“rt’arc ahl rreestuuocmg da i t”daknt1presetnp eueim“th llai, houtt te iighndhlmeii a”dhrsLdasi ggew

hneeays nyieurt .s twteahepeia ufratiegipleanarstnkoi twpsrre ooTkth as hesrkyinemanlsouarele dhnm novdnid nii s ubdrTufgd oi lvavtl ddcs elu e .drfwe acgspfay heahtta

hNug srr fggrtic eiscL so Pufk inadx-teroaeigy yp nh e1oa rdl v esasrni ti,ohtNltl ddGipwpeoilnarnivoTa d yd.Lno

hdsilqlel ii.nuoenvn ys sooaefedat .elin se j tdt rq3daiei,l2bos'e 3 o4uftbui2ggarwrjerlilsbnhoe iuepoteLIfewri o amummarseh a1 ,h$e lr -Zi7 Lu Mper loo sii s tstct)lp2rthunfl8 ui og.rcat yc e g nhah oyt aoy$dinne. rMeontnsr,2,ieeuwt vnher0nz5vii.a ec$’e ad(p larlnoladeres’3bvl

Please enable JavaScript to view this content.

Editor's note: You can comment on IBJ stories by signing in to your IBJ account. If you have not registered, please sign up for a free account now. Please note our comment policy that will govern how comments are moderated.

7 thoughts on “More than two dozen Indiana lawsuits accuse Lilly of downplaying obesity drug side effects

  1. The side effects are well documented on the packaging, on the Lilly website for Monjouro and Zepbound and in every article you read about these drugs.

    1. And where were their medical providers? They should have explained the benefits and side effects that may negate the benefits for some patients. I don’t blame Eli Lilly here, I blame the users.

    2. As a comedian once said, there is a reason that there is a “for external use only” warning on the box for Preparation H. Or 17 warning stickers on every step ladder sold today.

  2. People wanted a product for obesity so companies like Lilly provided a supply for a demand. Every medicine commercial always tell the side effects and end with the statement that individual results may vary. Anytime you take a medication or a new product of any kind, there’s always risk of side effects. Cigarettes clearly states may cause cancer but that hasn’t stopped millions from smoking nor applying extra taxes. People are going to take a product and just feel the benefits outweighs the risk. Not Lilly’s fault at all in my opinion.

  3. Been taking Mounjaro for about a year and a half. It’s a wonder drug for many diabetics like myself. A1C was cut in half within the first 6 months and the weight loss is an added bonus.

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Big business news. Teeny tiny price. $1/week Subscribe Now

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In

Your go-to for Indy business news.

Try us out for

$1/week

Cancel anytime

Subscribe Now

Already a paid subscriber? Log In